Company Overview

Integra LifeSciences Holdings Corporation is a global medical technology company focused on the development, manufacturing, and commercialization of products used in neurosurgery, orthopedics, and general surgery. The company operates within the broader medical devices and healthcare technology industries, supplying hospitals, surgical centers, and clinicians with specialized solutions designed to improve patient outcomes in complex surgical procedures.

Integra’s primary revenue drivers include neurosurgical instruments and implants, dural access and repair products, orthopedic extremity solutions, and regenerative tissue technologies. The company is recognized for its strong presence in neurosurgery and regenerative medicine, where it leverages proprietary biomaterials and established clinical adoption. Integra was founded in 1989 and has expanded over time through internal product development and targeted acquisitions, evolving into a diversified surgical technology platform with a strong emphasis on specialized, high-acuity procedures.

Business Operations

Integra operates through two primary business segments: Codman Specialty Surgical and Tissue Technologies. Codman Specialty Surgical includes neurosurgery, neurocritical care, and ear, nose, and throat surgical products, generating revenue through capital equipment, disposable instruments, and implantable devices. Tissue Technologies focuses on regenerative and reconstructive solutions, including dermal regeneration templates and wound care products used in plastic and reconstructive surgery.

The company generates revenue through direct sales in major markets and distributor relationships in select international regions. Integra controls a portfolio of proprietary technologies, including biomaterial platforms and surgical instrumentation systems, and operates manufacturing and R&D facilities in the United States and internationally. Its operations are supported by wholly owned subsidiaries rather than large-scale joint ventures, with integration across development, manufacturing, and commercial execution.

Strategic Position & Investments

Integra’s strategic direction centers on strengthening its leadership in neurosurgery and regenerative tissue technologies, while improving operational efficiency and portfolio focus. Growth initiatives include targeted innovation in neurocritical care, expansion of extremity orthopedic offerings, and lifecycle enhancements of established product lines. The company has also emphasized supply chain resilience and quality system investments following increased regulatory scrutiny across the medical device sector.

Historically, Integra has pursued growth through acquisitions to expand technology capabilities and market access, including the acquisition of ACell, Inc., which broadened its regenerative medicine portfolio. The company continues to invest in emerging surgical technologies and adjacent clinical indications that align with its core competencies, while periodically divesting or rationalizing non-core assets to maintain strategic focus.

Geographic Footprint

Integra LifeSciences is headquartered in North America, with its corporate headquarters located in Princeton, New Jersey. The company maintains a significant operational and commercial presence in the United States, which represents its largest revenue-generating market.

Internationally, Integra operates across Europe, Asia-Pacific, and Latin America, supported by regional offices, manufacturing sites, and distributor networks. Its products are sold in more than 100 countries, reflecting a broad global footprint and diversified exposure to developed and emerging healthcare markets.

Leadership & Governance

Integra is led by an executive team with experience across medical devices, healthcare operations, and global commercialization. The leadership emphasizes disciplined capital allocation, portfolio focus, and operational excellence, with a stated commitment to improving patient outcomes through clinically relevant innovation.

Key executives include:

• Jan De Witte – President and Chief Executive Officer
• Ari Garrett – Executive Vice President and Chief Financial Officer
• Glenn Coleman – Executive Vice President, Global Operations
• Michael Daly – Executive Vice President, Strategy and Corporate Development

The company is governed by a Board of Directors responsible for oversight of strategy, risk management, and executive compensation, consistent with public company governance standards in the United States.